By TAmiRNA GmbH
To get in touch with TAmiRNA GmbH, simply fill out the form below.
Subscribe to Supplier
TAmiRNA offers SARS CoV-2 RNA lab assay service as aid to Covid-19 testing
Biotech innovator TAmiRNA offers a SARS-Cov-2-PCR laboratory testing service for direct detection of SARS-CoV-2 viral RNA in biological samples. The RT-qPCR protocol implemented at TAmiRNA follows WHO guidelines for direct detection of a viral coronavirus infection and can serve as an aid in testing for Covid-19.
The service provides rapid (<3h) screening for positive Covid-19 cases using a CE-IVD multiplex assay for SARS-CoV-2 N-gene and an internal positive control from Austrian company Ingenetix (https://www.ingenetix.com/).
CoV-2 testing service features
TAmiRNA’s Cov-2 testing service enables rapid screening for positive cases based on detection of the SARS-CoV-2 N-gene, an internal positive control, and RNaseP, which helps to confirm proper sample collection. In subjects with a negative N-gene test result, a coronavirus infection can be ruled out. Subjects with a positive N-gene test result must undergo follow-up confirmation using a laboratory-developed assay to detect the SARS-CoV-2 specific E-gene.
Two service options are available: research-use testing or diagnostic testing with medical diagnosis report.
TAmiRNA also offers an immunochromatographic assay test kit that can identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM & IgG antibodies in human whole blood, serum or plasma sample.
Cov-2 testing applications
The TAmiRNA SARS Cov-2 testing service is intended as a routine diagnostic service for medical doctors and hospitals. Research services are intended to support academic and clinical research groups, pharmaceutical companies and research laboratories in their Covid-19 research projects. Nose and throat swab samples are eligible to be tested for medical diagnosis, while blood, serum, plasma, urine, or stool samples can be processed for research-use applications.
TAmiRNA provides its customers with an interactive electronic report, highlighting:
- whether a sample was tested positively or negatively for SARS-CoV-2
- the performance of all assay controls
- quantitative insights into viral RNA load
For diagnostic-use, a medical diagnosis report is provided.
SARS Cov-2 testing service benefits
The testing service can provide rapid (< 3h) information about infections with SARS-CoV-2 in human derived samples. High sensitivity and specificity are ensured based on the fact that all positive results will be confirmed with a second PCR test for SARS-CoV-2 E-Gene according to WHO recommendations.
Other benefits include:
- Flexible number of samples with no upper or lower limit restrictions
- Each assay requires only 100 µl of liquid nose or throat swab samples
- Quality control of all samples included
- Excellent data quality ensured, with all samples are handled by expert scientific teams
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.
More information available at: www.tamirna.com/.